LICENSE AND OPTION AGREEMENT



  
 Exhibit 10.1

  
 LICENSE AND OPTION AGREEMENT 
  
 THIS LICENSE AND OPTION AGREEMENT (the “Agreement”) is made
this 22nd day of October, 2002 (the “Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080
(“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea
(“LGLS”). LGLS and GS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 
  
 RECITALS 
  
 WHEREAS: 
  
 LGLS is the owner of all
right, title and interest in certain patents and know-how relating to Gemifloxacin (as hereafter defined); and 
  
 LGLS is the owner or licensee of certain patent rights, know-how, trademark rights and other intellectual property related to Gemifloxacin; and 
  
 LGLS wishes to license to GS the foregoing intellectual property rights to enable GS to develop and commercialize Gemifloxacin in the
Territory (as hereafter defined) and in the Field (as hereafter defined) and GS wishes to obtain such a license, all on the terms and conditions set forth herein; 
  
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, the Parties hereto agree as
follows: 
  
 ARTICLE 1 
 DEFINITIONS 
  
 When used in this Agreement, the following terms shall have the meanings indicated below. 
  
 1.1 “Active Pharmaceutical Ingredient” or “API” means Gemifloxacin in active bulk form
meeting the API Specifications. 
  
 1.2 “Additional
Indication” means an FDA-approved indication or formulation for Gemifloxacin within the Field other than the Initial Indication(s). 
  
 1.3 “Affiliate” means an individual, trust, business trust, joint venture, partnership, corporation, association or any other entity
which (directly or indirectly) is controlled by, controls or is under common control with a Party. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and
“under common control with”) as used with respect to any Party, shall mean the possession (directly or indirectly) 

  

 1 








 
of at least 50 percent of the outstanding voting securities of a corporation or comparable equity interest in any other type of entity. 
  
 1.4 “API Specifications” shall mean the specifications for
Active Pharmaceutical Ingredient attached hereto as Schedule 1.4. 
  
 1.5 “Combination Product” means a product consisting of Gemifloxacin and at least one other biologically active ingredient. 
  
 1.6 “Commercialization” means all activities undertaken relating to the marketing, promotion, distribution, use, storage, sale and offer
for sale of a Product in the Territory including, without limitation, advertising and any Phase IV clinical trials. 
  
 1.7 “Development” means: 
  
 (a) all activities relating to obtaining and/or maintaining Regulatory Approval of the Product in the Territory for the Initial Indication
including, without limitation, clinical trials and the preparation, submission, review and development of data or other information related thereto; 
  
 (b) Phase IV clinical trials supporting pre-launch and commercialization of the Product but not contributing to obtaining and/or
maintaining Marketing Authorization Applications of the Product for the Initial Indication and any Additional Indications in the Territory; 
  
 (c) all activities relating to obtaining and/or maintaining Marketing Authorization of Product for an Additional Indication in the
Territory, including Phase III clinical trials and the preparation, submission, review and development of data or other information related thereto; and 
  
 (d) all formulation studies for intravenous administration and any other new formulation of the Product. 
  
 The term “Development” shall not include process development or final finish or
fill of Product. 
  
 1.8 “EMEA” means the
European Agency for the Evaluations of Medical Products. 
  
 1.9 “FDA” means the U.S. Food and Drug Administration. 
  
 1.10 “Field” means the development, use, distribution, importation, storage, marketing, sale and offer for sale of Product for any human pharmaceutical or veterinary use. 
  
 1.11 “Final Product” means the Product in final form for
commercialization and distribution, labeled in accordance with applicable regulatory requirements and custom and meeting the Final Product Specifications. 
  
 1.12 “Final Product Specifications” means the specifications for Final Product attached hereto as Schedule 1.12. 
  

 2 








 1.13 “Fully Burdened Cost of Manufacture” means: ***** 
  
 1.14 “Gemifloxacin” means the racemic compound whose
mesylate is represented on Schedule 1.14 hereto as well as the pharmaceutically acceptable salts, physiologically hydolyzable esters, and solvates thereof, but excluding either enantiomer alone. The mesylate salt of Gemifloxacin is also known under
the trademark Factive®. 
  
 1.15 “GLAXO” means GlaxoSmithKline plc and its Affiliates.

  
 1.16 “GLAXO Agreement” means a certain
Termination and Transfer Agreement dated on or about October 14, 2002, by and among GLAXO (including certain of its Affiliates) and LGLS (including its Affiliate LG Chem Investment, Ltd.). 
  
 1.17 “GLAXO Know-how” means that Information relating to the
Product identified on Schedule 1.17 hereto. 
  
 1.18
“GLAXO Patents” means those patents and patent applications shown on Schedule 1.18 hereto and the equivalents thereof in all countries in the Territory and patents issuing from such patent applications, as well as divisionals,
continuations, continuations-in-part, reissues, reexaminations, renewals, extensions, utility models, additions and supplementary protection certificates to any such patents and patent applications which are necessary or useful for the development,
use, importation, manufacture, formulation, packaging, sale or offer for sale of Product in the Territory. 
  
 1.19 “GS” means Genesoft Pharmaceuticals, Inc. and its Affiliates. 
  
 1.20 “GS Know-how” means all Information relating to the Product developed by GS as a result of its
activities under this Agreement and any and all patent applications and patents covering or claiming any such Information. 
  
 1.21 “Information” means, whether or not patentable: (i) techniques and data including inventions, practices, methods, know-how, data
(including pharmacological, toxicological and clinical test data, regulatory submissions and data and analytical and quality control data), marketing, distribution, and sales data or descriptions, (ii) compounds, compositions of matter, assays and
biological materials, and (iii) dossiers of information necessary for Regulatory Approvals. 
  
 1.22 “Initial Indication(s)” means the first indication(s) for a Product approved by Regulatory Authorities anywhere in the Territory, formulated in the manner so approved. 
  
 1.23 “Launch” means the first commercial sale of a Product
in a country in the Territory by GS or any of its Affiliates or sub-licensees following receipt of Regulatory Approval in such country. 
  
 1.24 “*****” shall mean that compound represented on Schedule 1.24 hereto, as well as *****. 
  
 1.25 “LGLS” means LG Life Sciences, Ltd. and its Affiliates.

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 3 








 1.26 “LGLS Know-How” means all Information now or hereafter within the Control of LGLS
necessary or useful for the Development or Commercialization of the Product in the Territory, or for the filling, labeling and packaging of the Product anywhere in the world for use or sale in the Territory. 
  
 1.27 “LGLS Patents” means: (i) those patents and patent
applications shown on Schedule 1.27 attached hereto and the equivalents thereof in all countries in the Territory, (ii) all patents issuing from such patent applications, divisionals, continuations, continuations-in-part, reissues, reexaminations,
renewals, extensions, utility models, additions and supplementary protection certificates to any such patents and patent applications, and (iii) all patents and patent applications now or hereafter owned or controlled by LGLS necessary or useful for
the development, use, importation, formulation, packaging, sale or offer for sale of Product in the Territory. 
  
 1.28 “Marketing Authorization Application” means an application for Regulatory Approval required before commercial sale or use of the
Product in the Field in a regulatory jurisdiction in the Territory. 
  
 1.29 “Memorandum of Understanding” means an agreement between the Parties so titled and dated August 23, 2002. 
  
 1.30 “Net Sales” means, with respect to a Product that is not a Combination Product, the gross receipts representing sales of Product to
Third Parties by GS and its Affiliates and sub-licensees in the Territory, less deductions for the following items: 
  
 (i) reasonable transportation and insurance charges borne by the selling party, 
  
 (ii) sales and excise taxes or customs duties paid by the selling party and any other governmental charges imposed upon the
sale of the Product, 
  
 (iii) rebates or allowances actually
granted or allowed, including government and managed care rebates, 
  
 (iv) quantity discounts, cash discounts or chargebacks actually granted, allowed or incurred in the ordinary course of business in connection with the sale of the Product, and 
  
 (v) allowances or credits to customers, not in excess of the selling price of the Product, on account of governmental
requirements, rejection, outdating, recalls or return of the Product. 
  
 Sales
between GS and its Affiliates and sub-licensees shall be excluded from the computation of Net Sales and no royalties shall be payable on such sales. With respect to a Combination Product, the Parties shall in good faith endeavor to agree as to an
equitable and commercially reasonable means of defining “Net Sales.” If they are unable to reach such agreement, the matter shall be resolved as provided in Article 15, below. 
  
 1.31 “Patent Expenses” means governmental fees and the reasonable fees and expenses of outside counsel and
payments to Third Parties incurred after the Effective Date in 

  

 4 








 
connection with the preparation, filing, prosecution and maintenance of patents or patent applications, including the costs of patent interference,
opposition and revocation proceedings related thereto or to any Third Party patents containing claims which cover the manufacture, use, sale, offer for sale, importation or exportation of Product in the Territory. 
  
 1.32 “Product” means any compound including Gemifloxacin as
an active ingredient. 
  
 1.33 “Regulatory
Approvals” means all approvals (including pricing and reimbursement approvals) and licenses, registrations or authorizations of a Regulatory Authority, necessary for the use, import, storage, export, transport, filling, labeling, packaging
(to the extent that filling, labeling or packaging are carried out by GS or its Affiliates) or sale of a Product in a regulatory jurisdiction in the Territory. “Regulatory Approval” shall not, however, include any regulatory approvals
related to the manufacture of API and supply of API by LGLS to GS as contemplated herein. 
  
 1.34 “Regulatory Authority” means a governmental entity with the authority to grant Regulatory Approvals. 
  
 1.35 “Steering Committee” means the entity described in Article 3, below. 
  
 1.36 “Territory” means the United States of America, Canada, Mexico, France, Germany, the United Kingdom,
Luxembourg, Ireland, Italy, Spain, Portugal, Belgium, the Netherlands, Austria, Greece, Sweden, Denmark, Finland, Norway, Iceland, Switzerland, Andorra, Monaco, San Marino and Vatican City. 
  
 1.37 “Third Party” means an entity or person other than LGLS
or GS or their respective Affiliates. 
  
 1.38
“Trademarks” means those trademarks, trade names, domain names and logos identified on Schedule 1.38 hereto. 
  
 ARTICLE 2 
 PRODUCT DEVELOPMENT

  
 2.1 Scope of Development. Upon the Effective Date,
GS will assume lead responsibility for Development throughout the Territory for the Initial Indication(s), in consultation with LGLS. Following the Effective Date GS shall in good faith establish internal and external competence and controls
appropriate for the assumption of full responsibility for Development for the Initial Indication and, on notice to LGLS not later than the date on which first Regulatory Approval is received in the Territory LGLS shall, to the extent permitted by
law, transfer to GS ownership of all pending Marketing Authorization Applications and Regulatory Approvals including, without limitation, New Drug Application Nos. 21-158 and 21-376 (the “NDA”). Following the Effective Date, GS shall have
sole responsibility for *****; provided, however, that GS shall notify LGLS prior to filing a Marketing Authorization Application for any *****. 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 5 








 2.2 Development Effort. GS shall carry out its responsibilities under Section 2.1 using reasonable
efforts consistent with prudent business judgment, and in accordance with all applicable legal and regulatory requirements including, without limitation, then-current Good Laboratory Practices, and Good Clinical Practices. 
  
 2.3 Ownership of Regulatory Approvals. Following the transfer of
ownership provided in Section 2.1, above, all Marketing Authorization Applications shall be filed and maintained in the name of GS and GS shall be the owner of all resulting Regulatory Approvals. Through meetings of the Steering Committee, GS shall:
(i) keep LGLS informed regarding the schedule and progress for the preparation and submission of Marketing Authorization Applications in the Territory, and (ii) permit LGLS a reasonable opportunity to comment on such Marketing Authorization
Applications. 
  
 2.4 Communication with Regulatory
Authorities. GS shall have primary responsibility for dealing with Regulatory Authorities in the Territory, including filing all supplements and other documents with such authorities with respect to obtaining Regulatory Approvals, reporting all
adverse drug experiences related to the Product, and handling all Product complaints. At each meeting of the Steering Committee, GS shall provide to the Steering Committee a report describing the regulatory filing status of each Product throughout
the Territory. 
  
 2.5 Costs of Development. All
Development expenses shall be borne by GS. Without limiting the foregoing, within 30 days after receipt of an appropriate invoice from LGLS, GS shall reimburse LGLS for Development expenses in the Territory incurred between August 23, 2002 and the
Effective Date, as contemplated by the Memorandum of Understanding; provided, however, that the amount of reimbursement due for LGLS activities during such period in the Territory but outside of the United States of America shall not exceed $*****
unless GS shall have previously approved such excess. 
  
 ARTICLE 3 
 MANAGEMENT OF THE COLLABORATION 
  
 3.1 Steering Committee. Within 30 days after the Effective Date, LGLS and GS shall create a Steering Committee
consisting of an equal number of qualified representatives of each Party. A Party may change or replace its representatives on the Steering Committee as it deems appropriate, by notice to the other Party. Each Party will designate one of its members
of the Steering Committee as co-chairperson. The co-chairperson appointed by each Party shall be empowered to bind such Party to decisions of the Steering Committee to the extent contemplated herein. 
  
 3.2 Meetings of the Steering Committee. The Steering Committee shall
hold meetings at such times and places as shall be determined by the co-chairpersons. The meetings shall be held no less frequently than once every ***** months in the period from the Effective Date through the ***** year after the first Launch in
the United States of America, and not less than once every ***** months thereafter. Steering Committee meetings may be held in person or by telephone or video conference. The co-chairpersons shall alternate in keeping written 

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 6 








 
minutes that shall reflect the decisions taken at the meetings. Such minutes shall be circulated to the Steering Committee for review and approval within two
weeks after each meeting. 
  
 3.3 Function of the Steering
Committee. The Steering Committee shall coordinate the activities of the Parties under this Agreement, and perform such other functions as appropriate to further the purposes of this Agreement as determined by the Parties. 
  
 3.4 Decision Making. To the extent feasible, the Steering Committee
shall make decisions and take actions by consensus after an open discussion of the matters as to which decisions are being made. If no consensus can be reached, GS shall have the right to make final determinations regarding the Development and
Commercialization of the Product in the Territory to the extent not inconsistent with the express terms and provisions of this Agreement. Subject to Section 3.7, below, LGLS shall have the right to make final determinations regarding the development
and commercialization of Product outside the Territory. 
  
 3.5
Limitations of Powers of the Steering Committee. The Steering Committee shall have only such powers as are expressly delegated to it in this Agreement. The Steering Committee is not a substitute for the rights or the obligations of the Parties
and, inter alia, shall not have the authority to amend this Agreement. 
  
 3.6 Liaison Manager. Each Party will designate one of its members of the Steering Committee to act as its liaison manager to facilitate the performance of its rights and satisfaction of its obligations
hereunder. 
  
 3.7 Development and Commercialization Outside
the Territory. LGLS shall have the sole responsibility for development and commercialization of the Product outside of the Territory. LGLS shall regularly disclose to GS its plans for such development and afford GS a reasonable opportunity to
comment thereon. During the term of this Agreement, LGLS shall assure that its development of Product outside of the Territory (whether directly or through one or more sub-licenses) is conducted in a manner which minimizes the risk of disruption of
or other adverse effects on the development and commercialization of the Product in the Territory by GS as contemplated herein. Without limiting the foregoing: (i) following good faith consultation with GS, LGLS and its other licensees shall be free
to conduct clinical, regulatory, sales and marketing activities anywhere outside the Territory so long as they are for indications and/or formulations of Product consistent with label(s) for Product approved by Regulatory Authorities in the United
States or European Union, (ii) LGLS and its other licensees shall not conduct any pre-clinical activities with respect to the Product for any indication or formulation without the prior approval of GS, and (iii) LGLS and its other licensees shall
not conduct clinical, regulatory, sales or marketing activities with respect to any Additional Indication or a materially increased dosage or new means of administration of the Product without the prior approval of GS. At LGLS’s request, the
Parties shall in good faith discuss the matters for which GS approval or consultation is required pursuant subsections (ii) and (iii), above, at each meeting of the Steering Committee. 
  

 7 








  
 ARTICLE 4 

COMMERCIALIZATION 
  
 4.1 Commercialization Efforts. Commencing on the Effective Date, and subject to Section 4.3, below, GS shall be responsible for carrying out
Commercialization, at its sole expense, using reasonable efforts consistent with prudent business judgment. GS, directly or through one or more Affiliates or sub-licensees, shall launch in each country in the Territory using the same level of
diligence as GS would use with respect to a GS product with substantially the same market potential within in such country. 
  
 4.2 Pricing in the Territory. GS shall diligently obtain such Product pricing approvals as may be required in each country of the Territory. GS
shall be free to set the sale price of the Product in the Territory as it deems appropriate. 
  
 4.3 Co-Promotion. (a) LGLS shall have the option, exercisable on notice to GS prior to *****, to co-promote Product in the Territory commencing on January 1, 2008. If LGLS timely exercises this option, the
Parties shall promptly and in good faith negotiate a co-promotion agreement which establishes their respective rights and obligations, which agreement shall become effective on January 1, 2008. Such co-promotion agreement shall provide, inter
alia, that *****. 
  
 (b) If LGLS exercises its option
pursuant to subsection (a), above, all GS royalty obligations under Section 10.4, below, shall terminate with respect to Product sales occurring on or after January 1, 2008, but GS’s obligations under Section 10.2 shall remain in full force and
effect. 
  
 ARTICLE 5 
 MANUFACTURE AND SUPPLY 
  
 5.1 General. (a) The intent of the Parties is that: (i) between the Effective Date and July 1, 2004, LGLS shall supply to GS, and GS shall
exclusively purchase from LGLS all of GS’s requirements of Product in final form according to the Final Product Specifications, and (ii) following July 1, 2004 LGLS shall supply to GS, and GS shall purchase from LGLS all of GS’s
requirements of Product in bulk form according to the API Specifications, with final finish and fill to be provided either by LGLS or a Third Party, as provided in Section 5.1(b). The terms and conditions of LGLS supply pursuant to subsection (i)
are as set forth in this Article 5. The terms and conditions of LGLS supply pursuant to subsection (ii) shall be set forth in a supply agreement to be entered into as provided in Section 5.2. 
  
 (b) The Parties acknowledge that secure long-term supply of Product for GS is
essential to the success of the relationship reflected herein. No later than December 31, 2002 that Parties shall identify and, to the extent practicable, contractually commit to a long-term final finish and fill facility for the Product. Either the
Parties will jointly agree on a Third Party or LGLS shall commit to provide these services, either directly through the acquisition of a U.S.-based facility or by contract with a mutually acceptable third party. If LGLS elects to provide these
services, it shall notify GS to that effect no later than December 31, 2002. Regardless of whether final finish and fill is provided by LGLS or through a Third Party, GS shall have the right to approve the site selected for final finish and fill,
which approval shall not be unreasonably withheld. 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 8 








 5.2 Supply Agreement. Not later than December 31, 2002, the Parties shall complete and enter into
a supply agreement covering the supply of API by LGLS for the remainder of the term of this Agreement. Such supply agreement shall be consistent with the terms and conditions of this Agreement with respect to supply of Final Product and shall
include such other terms and conditions as the Parties may mutually agree including, without limitation, adequate provision for API shortages and supply interruption events to assure GS a secure long-term source of supply of API as well as license
to GS or its designee of the right to manufacture API in the event that LGLS fails to supply. The supply price for API provided under the Supply Agreement shall be equal to ***** percent of LGLS’s Fully Burdened Cost of Manufacturing for API
supplied thereunder, which shall in no event be ***** $***** per kg ***** $***** per kg. In addition, the supply agreement shall provide that: (i) if GS purchases more than ***** kg of API in any calendar year, the $***** supply price shall be
reduced by $***** for each ***** kg of API purchased in such year in excess of ***** kg, and (ii) the bulk supply price (including the ***** price) shall be renegotiated in good faith in the event that GS purchases more than ***** kg of API in any
12 month period. 
  
 5.3 Manufacturing Approvals. GS shall
be promptly notified of any proposed change in the process for the manufacture of Product pursuant to this Article 5 which potentially impacts the Marketing Authorization Applications or Regulatory Approval in the Territory including, without
limitation, any proposed change as to the site at which such manufacture is to occur. No Product incorporating any such proposed change and no Product manufactured at any proposed new facility shall be supplied by LGLS to GS hereunder without such
changes having first been approved by the appropriate Regulatory Authorities or by mutual agreement by the Parties, which regulatory approvals the Parties agree to pursue diligently following notice from LGLS of such proposed changes. 
  
 5.4 Specifications. LGLS warrants that the Product it supplies
hereunder shall meet the Final Product Specifications, and shall have been manufactured in accordance with all applicable laws and regulations including, without limitation, then-current Good Manufacturing Practice (“GMP”) compliance
standards. 
  
 5.5 Purchase Order and Forecasting. On or
before the later of: (i) December 31, 2002, or (ii) three business day after the date on which the NDA is accepted by the FDA, GS shall place a firm order for the amount of Product produced to Final Product Specifications which incorporates *****
metric tons of API. On or before January 1, 2003, GS shall provide to LGLS a non-binding forecast of the quantities of API to be manufactured during the forthcoming ***** period. As shall be provided in the supply agreement, this forecast shall be
updated by GS on or before ***** of each calendar year for the following *****. Within 45 days after receipt of each such forecast, LGLS shall provide to GS a good faith non-binding forecast of the Fully Burdened Cost of Manufacturing of the supply
forecast by GS. 
  
 Without limiting the foregoing, GS shall use
its best efforts to provide LGLS with supply orders for the delivery of Final Product or API within the following dates: 
  

	 	(i)	In ***** of each year, GS shall provide its supply orders for delivery during the ***** calendar quarter of such year; 

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 9 









	 	(ii)	In ***** of each year, GS shall provide its supply orders for delivery during the ***** calendar quarter of such year; 

  

	 	(iii)	In ***** of each year, GS shall provide its supply orders for delivery during the ***** calendar quarter of such year; and 

  

	 	(iv)	In ***** of each year, GS shall provide its supply orders for delivery during the ***** calendar quarter of the next year. 

  
 5.6 Delivery. The first order of ***** metric tons placed by GS
pursuant to Section 5.5 shall be delivered to GS no more than 30 days prior to the date on which the Parties in good faith anticipate receipt of final FDA approval of the Product for the Initial Indication(s). All deliveries of Product shall be made
***** as such term is defined in the INCOTERMS 2000. Title to the Product and all risks of loss or damage to Product shall remain with LGLS until Product is delivered to the carrier for shipment at the ***** point, at which time title and all risks
of loss or damage shall transfer to GS. LGLS agrees, in accordance with GS’s reasonable written instructions, to arrange for shipping and insurance, to be paid by GS from the ***** point to such locations as are requested by GS. 
  
 5.7 Inspection and Rejection. 
  
 5.7.1 GS shall, promptly upon receipt of a shipment
of Product from LGLS, inspect such shipment for defects that cause the Product to deviate from the Final Product Specifications (other than those resulting subsequent to delivery of Product to GS). If GS discovers such a defect, GS may reject such
defective Product, and shall promptly notify LGLS in writing of the rejection and the reason therefor. 
  
 5.7.2 Any rejection of defective or non-conforming Product by GS must occur within 40 days from delivery, failing which GS shall be
deemed to have accepted such shipment and to have irrevocably waived any claims it may have with respect to such shipment failing to meet the Final Product Specifications. 
  
 5.7.3 At the request of LGLS, GS shall either allow a representative of LGLS to inspect the rejected
Product and to make a determination as to the cause of the defect, or return a sample of the defective Product to LGLS for such inspection. If LGLS disagrees with GS’s determination, it shall notify GS within 30 days after inspection by LGLS as
provided in this Section 5.7.3, whereupon the Parties shall select an independent laboratory to draw a sample and determine whether such Product in fact conformed to the Final Product Specifications at the time of delivery to GS. The determination
of such independent laboratory shall be final. The Party whose determination was not accurate shall bear the cost of the independent analysis. 
  
 5.7.4 At the request and expense of LGLS, Product under the control of GS found to be defective shall be returned to LGLS (if by
permitted by law) or disposed of in accordance with LGLS’s lawful instructions. With respect to payments previously made by GS with respect to defective Product, GS shall be entitled, at its discretion, either to a refund or a credit against
amounts otherwise due to LGLS for supply hereunder. 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 10 








 5.8 Remedies. 
  
 5.8.1 If GS asserts that a shipment of Product was defective or non-conforming at the time of
delivery to GS, LGLS shall as soon as practical replace the rejected or disputed Product, pending resolution of the question of whether such original shipment was or was not defective. 
  
 5.8.2 The remedies set forth in this Article 5 are GS’s sole and exclusive remedies for claims
by GS against LGLS based on Product supplied by LGLS pursuant to this Agreement not conforming to the Final Product Specifications. 
  
 5.9 Supply Price and Payment Mechanism. 
  
 5.9.1 Product for use by GS non-commercial purposes (including, without limitation, clinical trials and for pre-Launch
compassionate use) shall be supplied by LGLS at its Fully Burdened Cost of Manufacturing. 
  
 5.9.2 Product for commercial use shall be supplied by LGLS at a supply price of ***** percent of its Fully Burdened Cost of
Manufacturing; provided, however that the price shall in no event be ***** $***** per finished tablet ***** $***** per finished tablet. 
  
 5.9.3 Payment for API and Final Product supplied by LGLS hereunder shall be due 30 days after delivery to GS’s premises
pursuant to Section 5.6, above; provided, however, that payment for the ***** metric tons of material ordered by GS pursuant to Section 5.5, above, shall be due in two equal installments. The first such installment shall be due 30 days after
delivery to GS’s premises pursuant to Section 5.6, above, and the second such installment shall be due 90 days after the first installment is due. 
  
 5.9.4 Notwithstanding the foregoing, in the event that any of the Product ordered by and delivered to GS pursuant to this Article 5
is unused by GS because of: (i) the expiration of FDA- or EMEA- approved Product dating, or (ii) commercial considerations which make such Product unusable (including, without limitation, because the Product is not approved by the FDA or the EMEA),
GS shall return such unused Product to LGLS (or at LGLS’s request and expense lawfully dispose of such Product). LGLS shall be responsible for the Fully Burdened Cost of Manufacture of the API component of such returned Product and, if GS has
previously paid for such Product, shall give GS a credit or prompt reimbursement for such amount. GS shall be responsible for the final finish and fill costs costs associated with such returned Product. 
  
 5.10 Release Certificate. LGLS shall provide to GS with each
delivery of Final Product a Release Certificate, a Certificate of Analysis and a Certificate of Compliance signed by a responsible person duly authorized by LGLS to certify the quality of the API delivered, each in a form reasonably acceptable to
GS. The Release Certificate shall, inter alia, state that the results of the agreed upon testing procedures are in compliance with the Final Product Specifications as well as any additional applicable requirements of Regulatory Authorities.
Without limiting the foregoing, unless expressly agreed by the Parties all Final Products supplied hereunder shall meet all release criteria established by the FDA or EMEA with respect to such Final Product. 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 11 








 5.11 Production Records. LGLS shall maintain records related to its manufacture and
handling of Final Product in accordance with the applicable rules and regulations and conditions of its licensure (including applicable rules of the FDA and EMEA and any other applicable regulatory requirements for record retention), for the longer
of: (i) five years after the date of manufacture of each batch of API, and (ii) the period required by applicable law. LGLS shall notify GS of any intent to destroy or dispose of records related to the manufacture or handling of API and allow GS an
opportunity to secure said records for additional storage periods in accordance with the written procedures of GS or its designee. Upon GS’s request with no fewer than five days’ prior notice, and at GS’s sole expense, LGLS shall send
to GS copies of the relevant documents or permit GS or an independent auditor selected by GS to have access to such records from time to time during ordinary business hours to verify compliance by LGLS with such rules and regulations. The provisions
set forth in this section shall survive termination of the Agreement for a period of 10 years. 
  
 5.12 Post Expiration Supply. The Parties recognize that following the expiration of the term of this Agreement GS may (or may not) continue to sell Product under the Trademark as contemplated by Sections
10.4 and 11.4. In the event that GS does so and in the further event that LGLS or any Affiliate of LGLS is at such time producing API in commercial quantities, LGLS shall offer to supply API to GS on a non-exclusive basis (i.e. GS shall be free to
purchase from Third Parties and LGLS shall be free to supply Third Parties) on commercially reasonable terms and conditions. 
  
 ARTICLE 6 
 CONFIDENTIALITY

  
 6.1 Confidentiality; Exceptions. The
receiving Party shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any Information and other information and materials furnished to it by the other Party pursuant
to this Agreement, or any provision of this Agreement that is the subject of an effective order of the Securities Exchange Commission granting confidential treatment pursuant to the Securities Act of 1934, as amended (collectively,
“Confidential Information”), except to the extent that it can be established by the receiving Party that such Confidential Information: 
  

	 	(i)	was already known to the receiving Party at the time of disclosure by the other Party; 

  

 12 









	 	(ii)	was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; 

  

	 	(iii)	became generally available to the public or otherwise part of the public domain after its disclosure by the disclosing Party and other than through any act or omission of the
receiving Party in breach of this Agreement; 

  

	 	(iv)	was disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the disclosing Party not to disclose such
information to others; or 

  

	 	(v)	was developed by the receiving Party’s employees without the use of or access to confidential information of the disclosing Party, as demonstrated by contemporaneous written
records of the receiving Party. 

  
 6.2
Authorized Disclosure. A Party may disclose Confidential Information of the other Party to the extent such disclosure is reasonably necessary in filing or prosecuting patent applications, prosecuting or defending litigation, complying
with applicable governmental regulations or conducting pre-clinical or clinical trials, provided that if a Party is required by law to make any such disclosure it will, to the extent practicable, give reasonable advance notice to the other Party of
such disclosure requirement and, except to the extent inappropriate in the case of patent applications, use reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed. In addition, each Party shall
be entitled to disclose Confidential Information, under a binder of confidentiality containing provisions as protective as those of this Article 6, to a Third Party for the purpose of carrying out activities authorized under this Agreement,
including disclosures to authorized or potential sub-licensees. Nothing in this Article 6 shall restrict any Party from using for any purpose outside the Field any Information developed by it during the course of the collaboration hereunder.

  
 6.3 Survival. This Article 6 shall survive the
expiration or termination of this Agreement for a period of five years; provided, however, that Confidential Information regarding LGLS’s manufacturing process for API shall be kept confidential by GS during the term of this Agreement and for a
further period of 10 years after the expiration or termination of this Agreement, subject to the exceptions in Section 6.1, above. 
  
 ARTICLE 7 
 INFORMATION AND REPORTS

  
 7.1 Information and Reports During Development and
Commercialization. 
  
 7.1.1 To the
extent permitted by law, GS and LGLS will each regularly disclose and make available to the other without charge all Information (including, without limitation, copies of all pre-clinical and clinical reports and training, marketing and promotional
materials) known to them. Without limiting the foregoing, promptly following the Effective Date, and at 

  

 13 








 
reasonable intervals thereafter, LGLS shall disclose and transfer to GS all LGLS Know-how and GLAXO Know-how and GS shall disclose and transfer to LGLS all
GS Know-how. 
  
 7.1.2 Upon reasonable
prior notice, each Party shall have the right to: (i) review the raw data generated in any clinical trial conducted by the other Party with respect to Product, (ii) visit clinical investigators and centers involved in performance of such clinical
trials, and (iii) discuss any such clinical trial and its results in detail with such clinical investigators. 
  
 7.2 Publicity Review. 
  
 7.2.1 Neither Party shall originate any publicity, news release, or other announcement disclosing any non-public terms of this
Agreement (collectively, “Disclosure”), without the prior prompt review and written approval of the other, which approval shall not be unreasonably withheld. Once specific information has been approved for disclosure, that information may
be reiterated in any subsequent Disclosure without further approval; provided, however, that the Parties shall, to the extent lawful, maintain the confidentiality of financial information contained in this Agreement and resulting from the activities
contemplated hereunder. 
  
 7.2.2
Notwithstanding Section 7.2.1, a Party may make any Disclosure it believes in good faith based upon the advice of its counsel or its auditors is required by applicable law and without the prior approval of the other Party may make such disclosures
as are required by the rules or regulations of the U.S. Securities and Exchange Commission or its relevant foreign counterpart. With respect to disclosures other than those required under such rules or regulations, prior to making such
Disclosure, the disclosing Party shall provide the other Party with a written copy or rendition of the materials proposed to be disclosed and provide the receiving Party with an opportunity to promptly review the proposed Disclosure. 
  
 7.3 Use of Names. Except as required by law or in furtherance of the
exercise of its rights hereunder, neither Party shall use the name of the other in any public announcement, press release or other public document related to this Agreement or the understanding reflected herein without the written consent of such
other Party, which consent shall not be unreasonably withheld or delayed. No such approval shall be required to republish a disclosure previously made or otherwise in the public domain. 
  
 7.4 Adverse Drug Events. Each Party shall promptly report to the other Party any adverse event observed during any
use of a Product. Prior to the first commercial sale of a Product in the Territory, the Parties shall in good faith enter into a data safety exchange agreement consistent with applicable law and regulatory requirements and practices in the United
States and European Union. 
  
 7.5 Recall 
  
 7.5.1 Any necessary recall of Product or any batch of
Product from the market in the Territory shall be effected by GS at GS’s reasonable discretion following, to the extent practicable, consultation with LGLS. Upon any Product recall, any then-pending orders of Product pursuant to Article 5,
above, shall be suspended until the reinstatement of the Product or revocation of the recall. 
  

 14 








 7.5.2 If any Product is recalled either: (i) as a result of an act or omission of
GS or its Third Party contractors or sub-licensees, or (ii) for any other reason not resulting in whole or part from an act or omission of LGLS or GLAXO, then GS shall bear all costs and expenses of such recall including, without limitation,
expenses or obligations to Third Parties, the cost of notifying end users and costs associated with shipment of any recalled Products from end users and destruction of such Products. 
  
 7.5.3 If any Product is recalled as a result of an act or omission of LGLS or its Third Party
contractors or sub-licensees, then LGLS shall bear all costs and expenses of such recall including, without limitation, refund of the supply price of the recalled Products, expenses or obligations to Third Parties, the cost of notifying end users
and costs associated with shipment of any recalled Products from end users and destruction of such Products. 
  
 7.5.4 If a recall of Products is necessary for reasons attributable in part to each of the Parties, then LGLS and GS shall be
responsible for a proportionate share of such recall costs on the basis of their respective responsibilities with respect to the event justifying the recall. 
  

7.5.5 In the event of a recall of Products, each Party shall immediately notify the other Party and cooperate in a manner which
is appropriate and reasonable under the circumstances. 
  
 7.6 Except as may be expressly provided herein and without prejudice to either Party’s responsibility for Third Party damages as provided for in Article 14, below, no claim for compensation, losses or damages (including, without
limitation, punitive, exemplary, incidental or consequential damages) may be made by one Party against the other as a result of any Product recall or any other act or omission of a Party pursuant to this Agreement (including, without limitation, the
termination of this Agreement by either Party). 
  
 ARTICLE 8

 PATENT RIGHTS 
  
 8.1 LGLS Patents and GLAXO Patents. (a) During the term of this Agreement, LGLS shall diligently maintain the LGLS Patents and the GLAXO
Patents in the Territory and shall use reasonable efforts to convert any currently pending or future filed patent applications into granted patents without undue delay. LGLS shall use patent counsel selected by LGLS and reasonably approved by GS for
such prosecution and maintenance and LGLS shall bear all related Patent Expenses. GS shall cooperate fully with LGLS in all such matters, at GS’s expense. 
  

(b) LGLS shall promptly disclose to GS the text of all LGLS Patents filed after the Effective Date as well as all information received after the
Effective Date concerning the institution or possible institution of any interference, opposition, re-examination, reissue, revocation, nullification or any official proceeding involving an LGLS Patent or GLAXO Patent any where in the Territory. GS
shall have the right to review all such pending applications and other proceedings and make recommendations to LGLS with respect thereto. LGLS shall keep 

  

 15 








 
GS promptly and fully informed of the course of patent prosecution and other proceedings and shall provide GS with copies of all substantive communications,
search reports and Third Party observations submitted to or received from patent offices throughout the Territory. All such disclosures shall be considered “Confidential Information” subject to Article 6, above. 
  
 8.2 Abandonment. LGLS shall be free, on at least 30 days’
prior notice to GS, to abandon and stop funding Patent Expenses related to any of the LGLS Patents in any country in the Territory. In such event, GS may, at its sole option, assume and continue prosecution or maintenance of the LGLS Patents and
GLAXO Patents in question, and shall thereafter bear all related Patent Expenses. Following such abandonment of a LGLS Patent by LGLS, LGLS shall have no further rights hereunder with respect to the LGLS Patent in question to the extent of such
abandonment, and the term “LGLS Patents” shall be deemed to have been modified accordingly. LGLS shall not abandon any GLAXO Patent nor stop funding Patent Expenses related thereto without the prior consent of GS, which consent shall not
be unreasonably withheld. 
  
 8.3 Infringement. If
either Party learns of an infringement or threatened infringement of the LGLS Patents or GLAXO Patents in the Territory in the Field it shall promptly notify the other Party and shall provide the latter Party with all information reasonably
available to the notifying Party evidencing such infringement or threatened infringement. Thereafter, the Parties shall in good faith consult and cooperate in abating such infringement or threatened infringement. 
  
 GS shall have the right, but not the obligation, to bring, defend and
maintain any appropriate suit or action for abatement of the infringement or threatened infringement of the LGLS or GLAXO Patents in the Territory and in the Field, at GS’s sole expense. If GS requests LGLS to join GS as a party in such suit or
action, LGLS shall execute all papers and perform such other acts as may be reasonably requested by GS, at GS’s expense. LGLS shall have the right to participate in any such suit or action using independent counsel, at its sole expense. Any
amount recovered by GS as a result of such suit or action shall first be applied to reimburse each of the Parties, pro rata, for any costs or expenses incurred in bringing, defending and maintaining any such action. The balance (the “Net
Recovery”) shall be for the sole benefit of GS. The Net Recovery shall be considered “Net Sales” with respect to the calendar quarter in which payment to GS was received, and royalties shall accordingly be paid on the amount of the
Net Recovery exclusively at the rate(s) specified in Section 10.3, below. The Net Recovery shall be considered “Net Sales” for purposes of calculating annual Net Sales in accordance with Milestone 3 and in Section 10.2, below. 

 
 If GS fails to initiate suit or action within 90 days after first notice
of infringement or threatened infringement of the LGLS Patents or the GLAXO Patents, or if having initiated such suit or action it thereafter diligently fails to prosecute such suit or action, LGLS shall have the right, but not the obligation, to
bring, defend and maintain any appropriate suit or action for abatement of the infringement or threatened infringement, at LGLS’s sole expense. If LGLS requests GS to join LGLS as a party in such suit or action, GS shall execute all papers and
perform such other acts as may be reasonably requested by LGLS, at LGLS’s expense. GS shall 

  

 16 








 
have the right to participate in any such suit or action using independent counsel, at its sole expense. Any amount recovered by LGLS as a result of such
suit or action shall first be applied to reimburse each of the Parties, pro rata, for any costs or expenses incurred in bringing, defending and maintaining any such action. The balance shall be divided equally between the Parties. The amount of any
recovery, net of the amounts necessary to reimburse the Parties as provided above shall be considered “Net Sales” for purposes of calculating annual Net Sales in accordance with Milestones 3 and in Section 10.2, below. If such recovery is
apportioned by the court such that portions thereof are attributed to infringing activity in different calendar years, or if such apportionment of the recovery can otherwise be readily ascertained, then such apportionment shall govern as to the
calendar year(s) in which Net Sales shall be deemed to have occurred for purposes of such Milestones. Otherwise, the amount of such recovery shall be apportioned equally over the number of calendar years in which infringement was found to have
occurred (or in the event of a settlement, over the number of calendar years in which it was alleged to have occurred). 
  
 8.4 Third Party Claims. If a Third Party asserts that a patent or other right owned by it is infringed by the development, manufacture,
import, use, sale or offer for sale of a Product by GS or its Affiliates or sub-licensees in the Territory in the Field, the Party first obtaining knowledge of such claim shall immediately provide the other Party notice of such claim and the related
facts in reasonable detail. In such event, the Parties shall determine how best to control the defense of any such claim. In the event the Parties cannot agree on the defense of such claim, such defense shall be controlled by GS with respect to
sales of Product in the Territory and by LGLS with respect to Product sales outside of the Territory. In each such case, the other Party shall have the right, at its own expense, to participate in such defense and to be represented in any such
action by counsel of its choice at its sole discretion. With respect to any such claim, the Party entitled to control defense shall also have the right to control settlement of such claim; provided, however, that no settlement shall be entered into
without the written consent of the other Party, which consent shall not be withheld unreasonably. 
  
 8.5 Ownership. Subject to Section 9.2, below, each Party shall have and retain sole and exclusive title to all inventions, discoveries and
know-how which are made, conceived, reduced to practice or generated solely by its employees or agents in the course of or as a result of this Agreement. Each Party shall own an equal undivided interest in all such inventions, discoveries and
know-how made, conceived, reduced to practice or generated jointly by the employees or agents of one Party and the employees or agents of the other Party. 
  
 ARTICLE 9 
 LICENSES and OPTIONS

  
 9.1 License Grant by LGLS. Subject to the
terms and conditions of this Agreement, LGLS hereby grants to GS and GS hereby accepts from LGLS a sole and exclusive license under the LGLS Patents, LGLS Know-How, GLAXO Patents, GLAXO Know-how to use, import, package, sell and offer for sale
Products within the Field in the Territory, as well as the exclusive right to use the Trademarks in the Territory in conjunction with the use or sale of Products. 
  
 9.2 License Grant by GS. Subject to the terms and conditions of this Agreement, GS hereby grants to LGLS and
LGLS hereby accepts from GS a non-exclusive royalty-free 

  

 17 








 
license under the GS Know-How to develop, use, import, formulate, package, sell and offer for sale Products outside of the Territory. Without limiting the
foregoing, the Parties agree that any patent application filed by or on behalf of GS prior to January 1, 2010 which covers or claims any novel use or formulation or means of administration of Product shall be jointly owned by the Parties regardless
of inventorship, and to the extent of LGLS’s ownership interest shall be considered an “LGLS Patent” for purposes of this Agreement. At LGLS’s request GS shall take all steps reasonably required to assign to LGLS its joint
ownership interest. 
  
 9.3 Sub-licensing. GS may
sub-license the license granted to it hereunder on prior notice to LGLS. LGLS may sub-license the license granted to it with respect to GS Know-how only upon prior agreement of GS, which may be withheld or granted in GS’s sole discretion.

  
 9.4 Use of Licenses. Neither Party shall use or
disseminate the Know-how of the other Party other than as expressly provided under this Agreement. In addition, GS warrants that it shall not adapt the GLAXO databases included in the GLAXO Knowhow or software operating on such databases for uses
unrelated to the uses of Product authorized herein. 
  
 9.5
*****. During the period commencing on the Effective Date and ending on December 31, 2002 (the “Negotiating Period”), the Parties shall in good faith negotiate the terms and conditions on which LGLS would grant to GS the
exclusive right to develop and commercialize ***** in the Territory. During the Negotiating Period LGLS shall not solicit or otherwise participate in any communications with any Third Party regarding the commercialization of ***** in the Territory.

  
 9.6 DNA Nanobinder Compounds. Schedule 9.6 hereto
describes GS’s DNA nanobinder compounds being developed for use in the fields of ***** (each, a “GS Option Field”). Promptly following the completion of the first Phase II clinical trial for a DNA nanobinder compound in each of the GS
Option Fields, GS shall notify LGLS and disclose to LGLS all available preclinical and clinical data regarding the use of such DNA nanobinder compound in the GS Option Field in question. During the ***** day period following such closure the Parties
shall in good faith negotiate the terms and conditions on which GS would grant to LGLS the exclusive right to develop and commercialize such DNA nanobinder compound in the GS Option Field in question in East Asia, including Japan. If the Parties are
unable to reach agreement by the end of such ***** day period, GS shall be free to develop and commercialize such DNA nanobinder compound in the GS Option Field in question as it sees fit. 
  
 9.7 *****. In the event that LGLS proposes to grant commercial
rights in the Territory with respect to ***** to a Third Party, it shall first offer such rights to GS on definitive terms. GS shall have 30 days after receipt of such offer to accept, failing which LGLS shall be free to offer such rights to a Third
Party on overall terms and conditions no more favorable to such Third Party than those offered to GS. In the event that LGLS proposes to develop and commercialize ***** in the Territory directly or in a collaboration with a Third Party, it shall
notify GS. Upon request by GS within 30 days following such notice, the Parties shall in good faith negotiate commercially reasonable terms and conditions on which GS would receive from LGLS an exclusive license with respect to such proposed
development and commercialization. If the Parties are unable to reach such agreement within 90 days after GS’s notice, at GS’s 

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 18 








 
request the terms of such an exclusive license shall be set by arbitration as provided in Article 15, below, and the Parties shall promptly execute a license
agreement consistent with the findings of the arbitration panel. 
  
 ARTICLE 10 
 PAYMENTS TO LGLS 
  

10.1 License Fee. Within 45 days following the Effective Date GS shall: (i) pay to LGLS a non-refundable license fee of $5.5 million, and
(ii) deliver to LGLS 4,749,659 fully-paid up and non-assessable shares of GS common stock (the “Shares”). GS represents and warrants that the Shares represent 14.0 percent of the total equity of GS on October 22, 2002, calculated on a
fully diluted basis. The rights and further characteristics of the Shares (including, without limitation, certain anti-dilution rights) are as set forth in the Stock Purchase Agreement and related documents attached hereto as Schedule 10.1.

  
 10.2 Milestone Payments. Within 30 days after
the achievement of each milestone set forth below, GS shall owe to LGLS a non-refundable milestone payment to LGLS in the amount set forth below. Each milestone payment shall be due only once, notwithstanding the number of Products actually
developed or commercialized by GS hereunder. Milestone payments 3 and 4, when earned by LGLS, shall be payable in two installments, the first of which shall be payable on the first day of July or the first day of January (which comes first following
the date on which the milestone was earned) and the second installment due six months thereafter. All other milestone payments shall be due 30 days after the relevant milestone event. 
  

				
	 Milestone Event

	  	Payment


	 1. Upon FDA approval of the Product for the Initial Indication. If at the time of such approval GS has not received and accepted the first
shipment of Product required pursuant to Section 5.8, one half of this milestone shall be deemed to have been earned, with the second half earned upon receipt and acceptance by GS of such shipment
	  	$	5.0 million
	 2. Upon an initial public offering (“IPO”) by GS of its shares or a sale of GS if, at the time of such IPO or sale, Product has been
approved for an Initial Indication
	  	$	8.0 million
	 3. Upon both: (i) approval for the first Additional Indication or approval of an IV formulation of the Product, and (ii) annual Net Sales in
the Territory reaching $*****
	  	$	*****

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 19 









				
	 4. Upon both: (i) approval for a second Additional Indication or approval of an IV formulation of the Product, and (ii) annual Net Sales in
the Territory reaching $*****
	  	$	*****
	 5. Upon approval of the Product for an Initial Indication in the United Kingdom
	  	$	*****
	 6. Upon approval of the Product for an Initial Indication in the first of Italy, Germany, France or Spain
	  	$	*****

  
 As used in this Section 10.2, “IV
formulation” shall mean a formulation of Product for intravenous administration. 
  
 10.3 Royalty Payments. In addition to the foregoing license fee and milestone payments, GS shall, subject to Sections 4.3 and 10.4, pay to LGLS royalties on Net Sales in each calendar year at the following
rates: 
  

			
	 Annual Net Sales

	  	Royalty Rate


	 on the first $*****
	  	*****
	 over $***** to $*****
	  	*****
	 over $***** to $*****
	  	*****
	 over $*****
	  	*****

  
 The Parties acknowledge that LGLS has
incurred a royalty obligation to GLAXO at a rate of ***** percent of Net Sales for the use of the GLAXO Patents, the GLAXO Know-how and the Trademarks (the “GLAXO Royalty”). During the first two years following first commercial sale of a
Product in the Territory, GS shall be solely responsible for payment of the GLAXO Royalty and shall pay all amounts so due to LGLS in accordance with Sections 10.7 through 10.11, below. Thereafter, LGLS shall be responsible for payment of the GLAXO
Royalty and shall indemnify GS and hold GS harmless from and against any claims by GLAXO as a result of such use. 
  
 10.4 Term of Royalty Obligations. GS’s obligation to make royalty payments pursuant to Section 10.3 with respect to a Product shall commence
on the date of the first commercial sale of such Product in a given country in the Territory and shall continue until the later of: (i) the expiration of the last to expire of the LGLS Patents and GLAXO Patents claiming or covering such Product in
such country, and (ii) 10 years after first commercial sale of such Product in such country. Following the expiration of GS’s royalty obligations, GS shall retain a non-exclusive, royalty-free right to use, sell and offer for sale Product in
the Territory, using LGLS Know-how and GLAXO Know-how licensed to GS as of the Effective Date and the exclusive right to use the Trademarks for such purposes. GS shall continue to pay to LGLS a royalty in return for such right to use the Trademark,
as provided in Section 11.4, below. 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 20 








 10.5 Royalty Reductions. If GS is required to pay royalties to Third Parties in order to exercise
the license granted to GS in Section 9.1, above, with respect to any Product in any country in the Territory, GS will be entitled to deduct ***** percent of the amount due to such Third Parties from the amounts due to LGLS pursuant to Section 10.3,
above, with respect to Net Sales of such Product in such country. In no event shall any such royalty reductions in any calendar quarter be more than ***** percent of the royalty payment due to LGLS with respect to such calendar quarter in a given
country. Any royalty reduction to which GS would otherwise be entitled may be carried forward by GS and used by GS in a future period (subject to the maximum reductions specified in this Section 10.5). 
  
 10.6 Royalties Payable Only Once; Sales to Affiliates and
Sub-Licensees. The obligation to pay royalties is imposed only once with respect to the same unit of each Product. Sales of Products between GS and its Affiliates or sub-licensees, or among such Affiliates and sub-licensees, shall not be subject
to royalties under Sections 10.3 but in such cases the royalties shall be calculated on the Net Sales by such Affiliates or sub-licensees to Third Parties. 
  
 10.7 Reports. GS shall deliver to LGLS, within 60 days after the end of each calendar quarter, reasonably detailed written accountings of Net Sales
that are subject to royalty payments due to LGLS for such calendar quarter. Such quarterly reports shall indicate gross sales on a country-by-country and Product-by-Product basis. When GS delivers such reports to LGLS, GS shall also deliver all
royalty payments due to LGLS hereunder for such calendar quarter. 
  
 10.8 Accounting and Audits. 
  
 (a) GS shall keep, and shall require its Affiliates and sub-licensees to keep, complete and accurate records of the latest five years of sales of Products on which royalties are due hereunder. For the purpose of verifying royalties due to
LGLS hereunder, LGLS shall have the right annually, at LGLS’s expense, to retain an independent certified public accountant selected by LGLS and reasonably acceptable to GS, to review such records in the location(s) where such records are
maintained by GS, its Affiliates or its sub-licensees upon reasonable notice and during regular business hours and under obligations of confidence. Results of such review shall be made available to both LGLS and GS. If the review reflects an
underpayment of royalties to LGLS such underpayment shall be promptly remitted to LGLS, together with interest at LIBOR plus ***** percent. If the underpayment of royalties is equal to or greater than ***** percent, then GS pay all of the costs of
such review. 
  
 (b) LGLS shall keep complete and
accurate records of the latest five years of supply hereunder sufficient to enable GS to confirm LGLS’s cost of goods. For the purpose of verifying cost of goods, GS shall have the right annually, at GS’s expense, to retain an independent
certified public accountant selected by GS and reasonably acceptable to LGLS, to review such records in the location(s) where such records are maintained, upon reasonable notice and during regular business hours and under obligations of
confidentiality. Results of such review shall be made available to both LGLS and GS. If the review reflects an overcharge by LGLS, such overcharge shall be promptly remitted to GS, together with interest calculated in the manner provided in Section
10.9, below. If the amount of such overcharge is equal to or greater than ***** percent, then LGLS pay all of the costs of such review. If the review reflects an 

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 21 








 
undercharge by LGLS, GS shall promptly refund the amount of the overpayment to LGLS, together with interest calculated at LIBOR plus ***** percent.

  
 10.9 Currency and Method of Payment. All payments due
or payable hereunder shall be made in US Dollars, delivered by wire transfer to such account as LGLS may identify from time to time on notice to GS. Royalty payments due hereunder with respect to sales not denominated in US Dollars shall be
converted using the applicable conversion rates quoted in the Wall Street Journal for buying US Dollars in accordance with U.S. generally accepted accounting principles, consistently applied. GS shall pay interest to LGLS on the amount of any
payments that are not paid on or before the date such payments are due under this Agreement at a rate of LIBOR plus ***** percent for the applicable period, calculated on the number of days such payment is delinquent. 
  
 10.10 Tax Withholding. The Parties shall use all reasonable and legal
efforts to reduce tax withholding on payments made to LGLS hereunder. Notwithstanding such efforts, if GS concludes that tax withholdings under the laws of any country are required with respect to payments due to LGLS, GS shall withhold the required
amount and pay it to the appropriate governmental authority. In such a case, GS will promptly provide LGLS with original receipts or other evidence reasonably desirable and sufficient to allow LGLS to document such tax withholdings adequately for
purposes of claiming foreign tax credits and similar benefits. No withholding deduction shall be made if LGLS furnishes lawful documentation demonstrating that the payment due is exempt from withholding according to the applicable convention for the
avoidance of double taxation between the United States and the Republic of Korea or other applicable law or treaty. 
  
 10.11 Blocked Payments. If, by reason of applicable laws or regulations in any country, it becomes impossible or illegal for GS or its Affiliates
or sub-licensees to transfer, or have transferred on its behalf, royalties or other payments due hereunder to LGLS, such royalties or other payments shall be deposited in local currency in the relevant country to the credit of LGLS in a recognized
banking institution designated by LGLS or, if none is designated by LGLS within a period of 30 days after inquiry from GS, in a recognized banking institution selected by GS and identified by notice to LGLS. 
  
 ARTICLE 11 
 TRADEMARKS 
  
 11.1 Responsible Party. GS, in consultation with LGLS, shall be responsible for maintaining the trademark Factive® in all countries in the Territory in which such mark is registered as of the Effective Date and for establishing and maintaining such trademark in
other countries in the Territory in which GS intends to Commercialize the Products, all at GS’s expense. 
  
 11.2 Infringement and Third Party Claims. Each party shall afford the other full cooperation in the defense and assertion of the Trademarks against
Third Parties. Absent agreement by the Parties, the provisions of Sections 8.2 and 8.3 shall apply by analogy with respect to infringement of or Third Party challenges to the Trademarks. 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 22 








 11.3 Termination of the Agreement. Following termination of this Agreement for any reason (but not
expiration of its term) GS will refrain from all further use of the Trademarks in the Territory.  
  
 11.4 Expiration of the Agreement. Following expiration of GS’s royalty obligations as provided in Section 10.4, above, and for so long as GS
continues to use the Trademark in the use or sale of Product, GS shall pay to LGLS a royalty equal to ***** percent of Net Sales. Such royalty shall be calculated and payable as provided in Sections 10.7 through 10.11, above. 
  
 ARTICLE 12 
 REPRESENTATIONS, WARRANTIES AND COVENANTS 
  
 12.1 Joint Representations and Warranties. Each of the Parties hereby represents and warrants to the other Party that this Agreement is a legal and
valid obligation binding upon such Party and enforceable in accordance with its terms. The execution, delivery and performance of the Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to
which it is a Party or by which it is bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 
  
 12.2 Representations and Warranties by LGLS. LGLS represents and warrants to GS that, as of the Effective Date, to
the actual knowledge of the executive officers and directors of LGLS: 
  
 (a) The information disclosed to GS during the course of its “due diligence” review of materials related to the Product was true and correct and, through the Effective Date, no material information has been
omitted from the “due diligence” disclosures made to GS by LGLS. 
  
 (b) No litigation exists or is threatened which would, if successful, adversely affect the rights granted to GS hereunder. 
  
 (c) All material safety issues related to the Product and to its manufacture have been disclosed to GS. 
  
 (d) All renewal fees related to the LGLS Patents, the GLAXO
Patents and the Trademarks have been paid in full. 
  
 (e) LGLS has good title to the LGLS Patents, the GLAXO Patents, the LGLS Know-how and the GLAXO Know-how and to the Trademarks (to the extent that filings thereof exist as of the Effective Date), free and clear of any liens or encumbrances.

  
 (f) As of the Effective Date LGLS has not
been served with notice of any interference proceedings with respect to the LGLS Patents or the GLAXO Patents and to the actual knowledge of LGLS, no such proceedings have been instituted. To the actual knowledge 

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 23 








 
of LGLS, as of the Effective Date there is no existing Third Party infringement of the LGLS Patents, the GLAXO Patents or the Trademarks. 
  
 (g) The information submitted to the Regulatory Authorities
with respect to the Product is true and correct. 
  
 (h) It has disclosed to GS the complete texts of all of the LGLS Patents and the GLAXO Patents existing as of the Effective Date as well as all information known to LGLS as of the Effective Date concerning the institution or possible
institution of any interference, opposition, re-examination, reissue, revocation, nullification or any official proceeding involving any of the LGLS Patents or GLAXO Patents any where in the Territory. 
  
 12.3 Covenants by LGLS. LGLS hereby covenants that: (i) the Transition
Plan contemplated by Section 2.1 of the GLAXO Agreement shall be completed in full not later than December 31, 2002, (ii) LGLS shall use its best efforts to finalize the Technology Transfer Agreement contemplated by Section 3.4 of the GLAXO
Agreement not later than January 31, 2003, and (iii) LGLS shall use its best efforts to finalize the Supply Agreement contemplated by Section 8.1 of the GLAXO Agreement, on terms and conditions consistent with this Agreement, not later than January
31, 2003. LGLS shall indemnify GS and hold GS harmless from and against any and all losses resulting from the failure by LGLS to complete the Transition Plan or to finalize the Technology Transfer Agreement or the Supply Agreement by the dates
specified in this Section 12.3. 
  

 24 








 In addition, the Parties recognize that Section 5.1 of the GLAXO Agreement purports to grant to LGLS only
non-exclusive rights with respect to certain GLAXO Knowhow, which if so construed would be inconsistent with Section 9.1 of this Agreement. LGLS shall indemnify GS and hold GS harmless from and against any and all losses and other direct
consequences of GLAXO (or its agent or licensee) exercising its rights reserved under Section 5.1 of the GLAXO Agreement in a manner inconsistent with GS’ rights under Section 9.1 of this Agreement; provided, however, that before making any
claim to such indemnification GS shall provide to LGLS with such evidence as is reasonably available to GS that the GLAXO Knowhow alleged by GS to have been used to GS’ detriment was in fact proprietary and not in the public domain. 

 
 Finally, the Parties recognize that Sections 7.1 and 7.2 of the GLAXO Agreement require
that unless certain events occur by June 30, 2004, GLAXO shall have the right to regain the Trademarks and the domain names listed in Appendix “G” to the GLAXO Agreement. If GLAXO shall hereafter assert that such events have not occurred
and seek the reconveyance of the Trademarks and domain names, LGLS covenants that it shall take all lawful steps to oppose such efforts by GLAXO for the benefit of GS and, if unsuccessful, shall indemnify GS and hold GS harmless from and against any
and all losses and other direct consequences resulting from the reconveyance to GLAXO of the Trademarks and domain names and the loss by GS of it rights hereunder with respect thereto. 
  
 12.4 Performance by Affiliates and Sub-licensees. The Parties recognize that each may perform some or all of its
obligations under this Agreement through Affiliates or, to the extent permitted, by sub-licensees. Nonetheless, each Party shall remain responsible and shall be the guarantor of the performance by its Affiliates and sub-licensees and shall cause its
Affiliates and sub-licensees to comply with the provisions of this Agreement in connection with such performance. In the event of a dispute arising out of the actions of an Affiliate or sub-licensee under this Agreement, each of GS and LGLS may
proceed directly against the other Party, without any obligation to first proceed against the Affiliate or sub-licensee. 
  
 ARTICLE 13 
 TERM AND TERMINATION

  
 13.1 Term. The term of this Agreement shall
commence on the Effective Date and shall expire upon the termination or expiration in all of the countries of the Territory of the royalty obligations as set forth in Section 10.4, above. 
  
 13.2 Termination for Material Breach. If either Party materially breaches this Agreement at any time, which breach is
not cured within ***** days of notice thereof from the non-breaching Party, the non-breaching Party shall have the right to terminate this Agreement on notice to the Party in breach following the expiration of such cure period; provided,
however, that if the Party alleged to be in breach shall have invoked the dispute resolution mechanism of Article 15 prior to the expiration of such cure period then termination shall not be effective until the sooner of abandonment of such
proceedings by the Party alleged to be in breach or completion of the dispute resolution proceedings and a non-appealable finding in arbitration in favor of the non-breaching Party. 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 25 








 13.3 Termination for Challenge to Patent Rights. If either Party challenges the validity and/or
enforceability of any of the other Party’s patent rights to which a license is granted hereunder, the latter Party shall have the right, to the extent lawful, to terminate the license granted pursuant to this Agreement with respect to the
challenged patents. 
  
 13.4 Unilateral Termination by GS.
GS may, at any time by delivery of 30 days’ prior notice to LGLS, elect to abandon its rights and obligations with respect to any country in the Territory, or to terminate this Agreement in its entirety. GS shall be entitled to suspend or
discontinue its Development, distribution and/or sale of any Product immediately upon notice to LGLS if new toxicity, safety findings or side effects shall occur that are so severe as to justify such discontinuation. Upon notice by GS pursuant to
this Section 13.4, this Agreement and all obligations of LGLS and GS hereunder with respect to the country or countries in question shall terminate and GS shall promptly transfer to LGLS all Marketing Authorization Applications and Regulatory
Approvals and the Trademarks with respect to the country or countries in question, as well as all other Information and know-how related to such country or countries. In the event that GS terminates its rights with respect to one or more countries
but not the entire Territory, then this Agreement shall remain in effect with respect to the countries not subject to such termination which countries shall, thereafter, be considered the “Territory.” 
  
 13.5 Bankruptcy. All rights granted hereunder are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code (the “Code”) licenses of rights to “intellectual property” as defined in Section 101(52) of the Code. The licensee Party under this Agreement shall
retain and may fully exercise all of its rights and elections under the Code, subject to performance by such Party of its obligations under this Agreement. In the event of the commencement of a bankruptcy proceeding by or against a Party under the
Code, the licensee Party shall, to the extent permitted by law, be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments thereof, which shall promptly be delivered to the
licensee Party, at its sole expense: (i) upon written request following commencement of a bankruptcy proceeding, or (ii) if not delivered pursuant to subsection (i), above, upon written request following the rejection in bankruptcy of this Agreement
by or on behalf of the bankrupt Party. In the event of a filing for bankruptcy or insolvency by a Party, such Party shall, to the extent permitted by law, confirm to the receiver, trustee or liquidator that the intellectual property rights licensed
hereunder are, notwithstanding such license, the sole property of the licensor Party and may not be disposed of by licensee except as expressly provided herein. 
  

13.6 Minimum Sales. LGLS shall have the right to terminate this Agreement on notice to GS in the event that GS’s aggregate gross sales of
Products in the Territory in the 12 month period commencing on the ***** anniversary of the date of first commercial of Product in the United States is less than $***** (which shall be reduced to $***** in the event that Product is approved in the
U.S. with a “black box” label warning); provided, however, that such right to terminate shall not apply in the event that GS sales of Product were at any time materially impeded by either force majeure or failure of supply outside of
GS’s control. 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 26 








 13.7 Effect of Termination 
  
 13.7.1 Termination of this Agreement shall not relieve the Parties of any liability, including any
obligation to make payments hereunder, which accrued hereunder prior to the effective date of such termination, nor preclude a Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of
this Agreement nor prejudice a Party’s right to obtain performance of any obligation which accrued hereunder prior to the effective date of such termination. Upon termination (but not expiration of the term of this Agreement), all licenses and
rights to Patents and Know-How granted hereunder shall terminate. 
  
 13.7.2 Upon termination of this Agreement (but not expiration of its term), all Confidential Information supplied by one Party shall be returned by the other Party except for one copy of such information
retained solely for legal archival or regulatory purposes. 
  
 13.7.3 Upon termination of this Agreement (but not expiration of its term), GS shall cooperate in the prompt transfer to LGLS of all Marketing Authorization Applications and Regulatory Approvals related to the
Products in the Territory, and shall diligently take such other actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer or reconveyance of rights hereunder to LGLS and the relinquishment of
such rights by GS. 
  
 13.7.4 Following
termination of this Agreement, GS shall have 120 days to sell any Product in its possession as of the effective date of termination, subject to its obligation to pay royalties to LGLS as provided hereinabove with respect to such sales. 

 
 13.8 Memorandum of Understanding. The Memorandum of Understanding
shall terminate effective as of the Effective Date. 
  
 13.9
Surviving Rights. The rights and obligations set forth in this Agreement shall extend beyond the term or termination of the Agreement only to the extent expressly provided for herein, or the extent that the survival of such rights or obligations
are necessary to permit their complete fulfillment or discharge. Without limiting the foregoing, the following shall survive the expiration or termination of this Agreement: Sections 5.11, 6.1, 6.2, 6.3, 7.4, 7.5, 7.7, 8.3, 8.4,, 10.7, 10.8, 11.2,
11.3, 11.4, and 13.7 and Articles 14, 15 and 16. 
  
 ARTICLE 14

 INDEMNIFICATION 
  
 14.1 Indemnification by GS. GS shall defend and hold LGLS and its agents, directors and employees harmless from and against any and all suits,
claims, actions, demands, damages, obligations, settlements, penalties, fines, costs, liabilities, expenses and/or loss claimed by a Third Party, including reasonable attorneys’ fees and expenses (collectively, “Losses”), resulting
from any breach of the representations or warranties of GS hereunder, or from the research, development, manufacture, use, handling, storage, sale or marketing of the Products by GS, its agents or sub-licensees, except to the extent such Losses
result from the negligence or willful misconduct of LGLS, and except to the extent of the indemnification by LGLS under Section 14.2. 
  

 27 








 14.2 Indemnification by LGLS. LGLS shall defend and hold GS and its agents, directors and
employees harmless from and against any and all Losses resulting from: (i) any breach of the representation or warranties of LGLS hereunder, (ii) from the research and development, manufacture, use, handling, storage, sale or marketing of the
Products or API (as the case may be) by LGLS or its agents, licensees or contract manufacturers, or (iii) from unknown defects in the Product or API as the case may be), except to the extent such Losses result from the negligence or willful
misconduct of GS, and except to the extent of the indemnification by GS under Section 14.1. 
  
 14.3 Procedure. A Party seeking indemnification under Section 14.1 or Section 14.2, shall inform the other Party of a claim as soon as reasonably practicable after it receives notice of the Third Party claim,
permit the indemnifying Party to assume direction and control of the defense of the Third Party claim (including the right to settle the claim solely for monetary consideration), and cooperate as requested (at the expense of the indemnifying Party)
in the defense of the Third Party claim. 
  
 14.4
Insurance. Promptly following the Effective Date and for a period of five years after the expiration or termination of this Agreement, each Party shall obtain and thereafter maintain, at its sole cost and expense, product liability insurance in
amounts which are reasonable and customary in the U.S. pharmaceutical industry for companies of comparable size and activities at the respective place of business of each Party. Such product liability insurance shall insure against all liability
arising as a result of activities completed or permitted under this Agreement (including, without limitation, liability for personal injury, physical injury and property damage). Each Party shall provide written proof of the existence of such
insurance to the other Party promptly upon request. 
  
 ARTICLE
15 
 DISPUTE RESOLUTION 
  
 15.1 Disputes. All disputes arising between the Parties hereunder or with respect to this Agreement shall be resolved solely as provided in this
Article 15. Any such dispute that the Parties are unable to resolve directly may be referred by either Party to the Steering Committee for resolution. If the Steering Committee is unable to resolve such dispute within 30 days after referral, either
Party may, on notice to the other, have such dispute referred to the CEOs of LGLS and GS for attempted resolution by good faith negotiation. If such individuals are unable to resolve such dispute within 30 days after referral, then either Party may
thereafter seek to resolve the dispute through arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with such rules, in English. The place of arbitration
shall be London, England. 
  
 15.2 Applicable Law. This
Agreement shall be governed by and construed under the substantive laws of the State of California, without regard to conflicts of law principles. 
  

 28 








 ARTICLE 16 
 MISCELLANEOUS 
  
 16.1
Assignment. 
  
 16.1.1 Either Party may
assign all of its rights and obligations under this Agreement to an Affiliate with the consent of the other Party, such consent not to be unreasonably withheld or delayed. 
  
 16.1.2 A Party may assign its rights or obligations under this Agreement to a non-Affiliate without
the approval of the other Party only in connection with a merger of that Party with a Third Party, acquisition of that Party by a Third Party, a similar reorganization affecting that Party, or in connection with the sale by that Party to a Third
Party of all or substantially all of the assets to which this Agreement relates. This Agreement shall survive any such merger, acquisition or reorganization of a Party with or into, or such sale of assets to, another party and no consent for such
merger, acquisition, reorganization or sale shall be required hereunder; provided, however, that in the event of such merger, acquisition, reorganization or sale, no intellectual property rights of the other merging or acquiring corporation
shall be included in the intellectual property licensed hereunder. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be
void. 
  
 16.1.3 In the event of an
assignment resulting from a merger or acquisition permitted pursuant to Section 16.1.2, above, LGLS and its successor entity shall endeavor to assure that GS confidential information provided under this Agreement is kept confidential and distributed
within the successor entity solely to the limited extent necessary in order to satisfy such entity’s obligations, and exercise such entity’s rights, with respect to Gemifloxacin hereunder. 
  
 16.2 Force Majeure. Except as otherwise expressly provided herein,
neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses on account of failure of performance by the defaulting Party if the failure is occasioned by government action, war, acts of gods, or any other
similar or dissimilar cause beyond the control of the defaulting Party, provided that the Party claiming force majeure has exerted all reasonable efforts to avoid or remedy such force majeure. 
  
 16.3 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  
 16.4 Notices. All notices hereunder shall be in writing and shall be deemed given if delivered personally or by
facsimile transmission with confirmed answer-back, mailed by registered mail (return receipt requested), postage prepaid, or sent by internationally recognized express courier service, to the Parties at the addresses first set forth above (or at
such other address for a Party as shall be specified by like notice; provided, that notices of a change of address shall be effective only upon receipt thereof). Notice by personal delivery shall be 

  

 29 








 
deemed effective upon receipt. Notice by courier or registered mail shall be deemed effective three business dates after the date sent. Notice by fax shall
be deemed effective upon receipt by the sending Party of confirmation of receipt of the fax by the receiving Party. 
  
 16.5 Waiver. The waiver from time to time by either of the Parties of any of their rights or their failure to exercise any remedy shall not operate
or be construed as a continuing waiver of same or of any other of such Party’s rights or remedies provided in this Agreement. 
  
 16.6 Severability. If any term, covenant or condition of this Agreement or the application thereof to any Party or circumstance shall, to any
extent, be held to be invalid or unenforceable, then the remainder of this Agreement, or the application of such term, covenant or condition to Parties or circumstances other than those as to which it is held invalid or unenforceable, shall not be
affected thereby and each term, covenant or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by law. In such event the Parties shall in good faith attempt to reform this Agreement to reflect the intent and
anticipated consequences of the invalidated or unenforceable provision, to the extent possible in a way that is lawful. 
  
 16.7 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against either Party, irrespective of which Party may be deemed to
have authored the ambiguous provision. 
  
 16.8 Headings.
The section and article heading contained herein are for the purposes of convenience only and are not intended to define or limit the contents of said sections or articles. 
  
 16.9 Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an original, but
which together shall constitute one and the same instrument. 
  
 16.10 Entire Agreement. This Agreement (including all Schedules hereto) sets forth all the covenants, promises, agreements, warranties, representations, conditions and understanding between the Parties hereto and supersedes and
terminates all prior agreements and understanding between the Parties. 
  
 16.11 Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER HEREUNDER FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE.

  

 30 








 IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by their proper officers as of
the Effective Date. 
  

									
	GENESOFT PHARMACEUTICALS, INC.	 	 	 	LG LIFE SCIENCES, LTD.
					
	 By:
	 	 /s/ David B. Singer
	 	 	 	 By:
	 	 /s/ Heung Joon Yang

					
	 Its:
	 	 Chairman and CEO
	 	 	 	 Its:
	 	 President and CEO


  









  
 Schedule 1.4

 API Specification 
  
 Chemical Name 
  
 (R,S) - 7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, monomethanesulfonate 
  
 

 
  
 Description (Visual examination)

  
 White to light brown solid 
  
 Identification (Nujol Mull or includes mesylate counte-ion) 
  
 The IR spectrum of the sample agrees with that of the reference standard similarly prepared
and measured 
  
 Water Content (Karl Fischer, USP<921>method 1a,
GT24)1 
  
 4.0% - 7.0% w/w 
  
 High Molecular Weight Impurities (TLC, RM G-12D) 
  
 NMT 100% compared to the reference standard 
  



	1	This test will be done for at least 10 receivings. Use 250 mg of sample/50mL methanol and dissolve for not less than 30 minutes. 









  
 Schedule 1.12

 Final Product Specification 
  
 Material: Factive TM Tablet 320mg

  
 Tablet 
  
 Description (Visual) 
  
 A white to off-white, oval, film-coated tablet with breaklines in both faces and debossed
with GE 320 on both faces 
  
 Identification 
  
 HPLC(MF-3A) 
  
 The retention time of the chromatogram for the sample must correspond to that of the reference standard, similarly prepared 
  
 Infra-red spectroscopy (USP<197M>) 
  
 The infrared spectrum of the sample, as a mineral oil dispersion, should exhibit the same
maxima as a similar preparation of a reference standard 
  
 Gemifloxacin
content (MF-3A) 
  
 90.0-110.0% of label claim (288.0 to 352.0 mg per
tablet) 
  
 Uniformity of dosage unit by weight variation
(USP<905>) 
  
 Meets USP Requirements 
  
 Dissolution (MF-3B, USP<711>Paddle, 0.01M HC1, 50rpm) 
  
 Meets USP Requirements (Q=70%) in 30 minutes 
  
 Moisture content (MF-3C) 
  
 Not more than 6.0% 
  
 Degradation products (MF-3A) 
  

			
	 SB-332410
	  	Not more than 0.7% Peak Area Ratio
	 Any unspecified impurities
	  	Not more than 0.1% Peak Area Ratio
	 Total related substances
	  	Not more than 1.5% Peak Area Ratio

  
 Package 
  
 ***** 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 









  
 Schedule 1.14

 Gemifloxacin 
  
 Chemical Name 
  
 (R,S)-7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- 1,8-naphthyridine-3-carboxylic acid, monomethanesulfonate 
  
 

 
  









  
 Schedule 1.17

 GLAXO Knowhow 
  
 “GLAXO Knowhow” shall mean the following inventions and discoveries, to the extent that they were conceived, devised and/or reduced to practice by GSK as of the
September 30, 2002, and which are not yet the subject of patent applications: 
  

	 	(i)	***** 

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 









  
 Schedule 1.18

 GLAXO Patents 
  

													
	 	  	Country

	  	 Appl.
 No.

	  	 Appl.
 Date

	  	 Patent
 No.

	  	 Grant
 Date

	  	 Exp.
 Date


	 *****
	  	*****	  	*****	  	*****	  	*****	  	*****	  	*****
							
	 P50929 P + X1
	  	US	  	99-400144	  	21SE1999	  	6331550	  	18DE2001	  	 
	 (Family of P50928
	  	*****	  	*****	  	*****	  	*****	  	 	  	 
	 Bacteria 1)
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 P50929X1D1
 Family of P50928
 Bacteria 1
	  	US	  	09/976323	  	12OC2001	  	6455540	  	24SE2002	  	21SE2019
							
	 P50952
	  	*****	  	*****	  	*****	  	 	  	 	  	 
	 Bacteria 1
	  	US	  	09/395851	  	14SE1999	  	6340689	  	22JA2002	  	 
	 Family of P50928
	  	*****	  	*****	  	*****	  	*****	  	 	  	 
	 Bacteria 1
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 P50953
	  	*****	  	*****	  	*****	  	*****	  	 	  	 
	 Bacteria 1
	  	US	  	09/399855	  	21SE1999	  	6262071	  	17JL2001	  	 
	 Family of P50928
	  	 	  	 	  	 	  	 	  	 	  	 
	 Bacteria 1
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 *****
	  	*****	  	*****	  	*****	  	*****	  	*****	  	*****

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 









  
 Schedule 1.24

  
 ***** 
  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 









  
 Schedule 1.27

 LGLS Patents 
  

													
	 	  	Country

	  	 Appl.
 No.

	  	 Appl.
 Date

	  	 Patent
 No.

	  	 Grant
 Date

	  	 Exp.
 Date


	 *****
	  	*****	  	*****	  	*****	  	*****	  	*****	  	*****
							
	 LB20304
	  	US	  	08/490,978	  	15.06.95	  	5,633,262	  	27.05.97	  	15.06.2015
	 Novel quinoline
	  	*****	  	*****	  	*****	  	*****	  	*****	  	*****
	 carboxylic acid
 derivatives having
 7-(4-aminomethyl-3-oxime) pyrrolidine
 substituents and
 processes for their
 preparation
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 LB20304
	  	US(CIP)	  	08/825,992	  	04.04.97	  	5,776,944	  	07.07.98	  	 
	 7-(4-Aminomethyl-3
	  	*****	  	*****	  	*****	  	 	  	 	  	 
	 methyloxy-iminopyrrolidin-1-yl)-1 - cyclopropyl-6-
 fluoro-4-oxo-1,4-
 dihydro-1,8-
 naphthyridine-3-
 carboxylic acid and
 the process for the
 preparation thereof
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 *****
	  	*****	  	*****	  	*****	  	*****	  	*****	  	 
							
	 Continuation of US
 09/049,024 which
 claims the treatment
 method
	  	US (Div 4)	  	09/188,063	  	09.11.98	  	5,962,468	  	05.10.99	  	 
							
	 *****
	  	*****	  	*****	  	*****	  	*****	  	*****	  	*****

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 









  
 Schedule 1.38

 Trademark 
  
 FACTIVE 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


							
	 Andorra
	 	5	 	Registered	 	12191	 	19/11/1998	 	11723	 	19/11/1998
	
	 5) MEDICINES FOR HUMAN USE; PHARMACEUTICAL PRODUCTS; REMEDIES FOR HUMAN USE

							
	 Austria
	 	5	 	Registered	 	AM2218/96	 	12/04/1996	 	166024	 	30/08/1996
	
	 5) PHARMACEUTICAL AND MEDICAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE

							
	 Canada
	 	 	 	Filed	 	79870600	 	01/12/1995	 	 	 	 
	
	 ) ANTI-VIRAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE

							
	 Denmark
	 	5	 	Registered	 	VA199600283	 	16/01/1996	 	VR199600791	 	02/02/1996
	
	 5) PREPARATIONS AND SUBSTANCES FOR THE TREATMENT OF RESPIRATORY DISORDERS

							
	 European Union
	 	5	 	Registered	 	000950352	 	08/10/1998	 	000950352	 	31/01/2000
	
	 5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES

							
	 Finland
	 	5	 	Registered	 	T199802485	 	21/07/1998	 	214152	 	14/05/1999
	
	 5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE; SPECIFICALLY AN ANTI-BACTERIAL

							
	 France
	 	5	 	Registered	 	95600030	 	07/12/1995	 	95600030	 	07/12/1995
	
	 5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE


  










													
							
	Greece	 	5	 	Registered	 	128137	 	31/01/1996	 	128137	 	17/03/1998
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE
							
	Iceland	 	5	 	Registered	 	351/1996	 	12/03/1996	 	1216/1996	 	25/11/1996
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE, INCLUDING AN ANTI-VIRAL
							
	Ireland	 	5	 	Registered	 	95/8291	 	05/12/1995	 	171292	 	05/12/1995
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE
							
	Italy	 	5	 	Registered	 	MI95CO12228	 	06/12/1995	 	00733838	 	14/11/1997
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE
							
	Mexico	 	5	 	Registered	 	260065	 	17/04/1996	 	542746	 	27/02/1997
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE
							
	Monaco	 	5	 	Registered	 	020534	 	17/02/1999	 	99.20373	 	17/02/1999
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES
							
	Netherlands Antilles	 	5	 	Registered	 	D-900	 	24/12/1998	 	21301	 	09/02/1999
	
	5) PHARMACEUTICAL, VETERINARY AND SANITARY PREPARATIONS; DIETETIC SUBSTANCES ADAPTED FOR MEDICAL USE, FOOD FOR BABIES; PLASTERS, MATERIALS FOR DRESSINGS; MATERIAL FOR STOPPING
TEETH, DENTAL WAX; DISINFECTANTS; PREPARATIONS FOR DESTROYING VERMIN; FUNGICIDES, HERBICIDES
							
	Norway	 	5	 	Filed	 	200112664	 	25/10/2001	 	 	 	 
	
	5) ANTI-INFECTIVE PREPARATIONS FOR HUMAN USE
							
	Norway	 	5	 	Registered	 	19961885	 	19/03/1996	 	182042	 	15/05/1997
	
	5) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF RESPIRATORY DISORDERS

  










													
							
	Portugal	 	5	 	Registered	 	314842	 	15/01/1996	 	314842	 	14/10/1996
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE
							
	Spain	 	5	 	Registered	 	2184599	 	18/09/1998	 	2184599	 	05/10/1999
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE
							
	Sweden	 	5	 	Registered	 	95-14489	 	13/12/1995	 	315811	 	09/08/1996
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE
							
	Switzerland	 	5	 	Registered	 	00225/1996	 	16/01/1996	 	433454	 	30/12/1996
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE, EXCEPT FOR DISINFECTANT OR STERILIZATION PURPOSES
							
	United Kingdom	 	5	 	Registered	 	2041126	 	13/10/1995	 	2041126	 	13/10/1995
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE, BUT NOT INCLUDING ANY SUCH GOODS BEING DISINFECTANTS OR STERILIZING PREPARATIONS
							
	USA	 	5	 	Registered	 	75045500	 	19/01/1996	 	2281877	 	28/09/1999
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE, NAMELY, ANTI-VIRALS AND ANTI-INFECTIVES

  
 FACTIVE DEV. 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


							
	Andorra	 	5	 	Registered	 	 	 	 	 	14905	 	14/07/2000
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES

  










													
	 Austria
	 	5	 	Registered	 	AM4560/2000	 	21/06/2000	 	195230	 	04/04/2001
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES
							
	 Canada
	 	 	 	Filed	 	1066283	 	06/07/2000	 	 	 	 
	
	) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES, NAMELY ANTI-VIRALS AND ANTI-INFECTIVES
							
	 European Union
	 	5	 	Registered	 	001721273	 	23/06/2000	 	001721273	 	29/05/2001
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES
							
	 Iceland
	 	5	 	Registered	 	2304/2000	 	29/06/2000	 	1149/2000	 	01/09/2000
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES
							
	 Mexico
	 	5	 	Registered	 	444544	 	28/08/2000	 	688725	 	28/02/2001
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES
							
	 Monaco
	 	5	 	Registered	 	022925	 	06/07/2001	 	01.22636	 	06/07/2001
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES
							
	 Netherlands Antilles
	 	5	 	Registered	 	D-395	 	10/07/2000	 	22486	 	01/11/2000
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES
							
	 Norway
	 	5	 	Registered	 	200007413	 	27/06/2000	 	205945	 	07/12/2000
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES
							
	 Switzerland
	 	5	 	Registered	 	07922/2000	 	03/07/2000	 	480382	 	18/01/2001
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE, EXCEPT FOR DISINFECTANT OR STERILISATION
							
	 United Kingdom
	 	5	 	Registered	 	2236543	 	20/06/2000	 	2236543	 	20/06/2000
	
	5) PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES FOR HUMAN USE; BUT NOT INCLUDING ANY SUCH GOODS BEING DISINFECTANTS OR STERILISING PREPARATIONS

  










									
	 USA
	 	16	 	Filed	 	76054224	 	23/05/2000
	
	16) PRINTED EDUCATIONAL MATERIALS, NAMELY, BROCHURES AND PAMPHLETS CONCERNING HEALTHCARE RELATED ISSUES AND PHARMACEUTICAL TREATMENTS FOR INFECTION
					
	 USA
	 	42	 	Filed	 	76052305	 	18/05/2000
	
	42) PROVIDING INFORMATION, VIA GLOBAL COMPUTER NETWORKS, CONCERNING INFECTIOUS DISEASES, INCLUDING RESPIRATORY TRACT INFECTIONS AND TREATMENTS THEREFORE
					
	 USA
	 	5	 	Filed	 	76054223	 	23/05/2000
	
	5) PHARMACEUTICALS, NAMELY, ANTIBIOTICS

  
 FACPAC3 DAY 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


	 USA
	 	5	 	Filed	 	78086704	 	03/10/2001	 	 	 	 
	
	5) PHARMACEUTICALS, NAMELY, ANTIBIOTICS IN TABLET FORM PACKAGED IN CONVENIENCE CARTONS TO ENSURE PATIENT COMPLIANCE WITH RESPECT TO COMPLETE COURSE OF MEDICATION

  









 FACPAC3 (STYLIZED) 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


	 USA
	 	5	 	Filed	 	78034657	 	10/11/2000	 	 	 	 
	
	5) PHARMACEUTICALS, NAMELY, ANTIBIOTICS IN TABLET FORM PACKAGED IN CONVENIENCE CARTONS TO ENSURE PATIENT COMPLIANCE WITH RESPECT TO COMPLETE COURSE OF MEDICATION

  
 FACPAC5 AND DEV. 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


	 USA
	 	5	 	Filed	 	78028793	 	03/10/2000	 	 	 	 
	
	5) PHARMACEUTICALS, NAMELY, ANTIBIOTICS IN TABLET FORM PACKAGED IN CONVENIENCE CARTONS TO ENSURE PATIENT COMPLIANCE WITH RESPECT TO COMPLETE COURSE OF MEDICATION

  
 FACPAC5 DAY 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


	 USA
	 	5	 	Filed	 	78086709	 	03/10/2001	 	 	 	 
	
	5) PHARMACEUTICALS, NAMELY, ANTIBIOTICS IN TABLET FORM PACKAGED IN CONVENIENCE CARTONS TO ENSURE PATENT COMPLIANCE WITH RESPECT TO COMPLETE COURSE OF MEDICATION

  









 FACPAC5 (STYLIZED) 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


	 USA
	 	5	 	Filed	 	78032521	 	26/10/2000	 	 	 	 

  
 5) PHARMACEUTICALS, NAMELY,
ANTIBIOTICS IN TABLET FORM PACKAGED IN CONVENIENCE CARTONS TO ENSURE PATIENT COMPLIANCE WITH RESPECT TO COMPLETE COURSE OF MEDICATION 
  
 FACPAC7 AND DEV. 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


	 USA
	 	5	 	Filed	 	78028794	 	03/10/2000	 	 	 	 

  
 5) PHARMACEUTICALS, NAMELY,
ANTIBIOTICS IN TABLET FORM PACKAGED IN CONVENIENCE CARTONS TO ENSURE PATIENT COMPLIANCE WITH RESPECT TO COMPLETE COURSE OF MEDICATION 
  
 FACPAC7 DAY 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


	 USA
	 	5	 	Filed	 	78086707	 	03/10/2001	 	 	 	 

  
 5) PHARMACEUTICALS, NAMELY,
ANTIBIOTICS IN TABLET FORM PACKAGED IN CONVENIENCE CARTONS TO ENSURE PATIENT COMPLIANCE WITH RESPECT TO COMPLETE COURSE OF MEDICATION 
  









 FACPAC7 (STYLIZED) 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


	 USA
	 	5	 	Filed	 	78032520	 	26/10/2000	 	 	 	 

  
 5) PHARMACEUTICALS, NAMELY,
ANTIBIOTICS IN TABLET FORM PACKAGED IN CONVENIENCE CARTONS TO ENSURE PATIENT COMPLIANCE WITH RESPECT TO COMPLETE COURSE OF MEDICATION 
  
 FAST.ACTIVE.FACTIVE 
  

													
	 Country

	 	 Class(es)

	 	 Status

	 	 App. No.

	 	 App. Date

	 	 Reg. No.

	 	 Reg. Date


	 USA
	 	16	 	Filed	 	76092242	 	19/07/2000	 	 	 	 

  
 16) PRINTED EDUCATIONAL MATERIALS,
NAMELY BROCHURES, PAMPHLETS, AND BOOKLETS CONCERNING RESPIRATORY TRACT INFECTIONS AND TREATMENTS THEREOF 
  

													
	 USA
	 	5	 	Filed	 	76092240	 	19/07/2000	 	 	 	 

  
 5) PHARMACEUTICALS, NAMELY ANTIBIOTICS

  
 FACTIVE.COM 
  
 FACTIVE.ORG 
  
 FACTIVE.NET 
  
 FACTIVE.BIZ 
  
 FACTIVE.INFO 
  









 Schedule 9.6 
 DNA Nanobinder Compounds 
  
 DNA
nanobinder compounds are compounds that (a) *****, (b) *****, (c) ***** and (d) *****. DNA nanobinder compounds include, but are not limited to, compounds covered by one or more of the following GS patent applications: 
  

	
	
	US Patent Application No. *****
	
	US Patent Application No. *****
	
	US Patent Application No. *****
	
	US Provision Patent Application No. *****
	
	US Patent Application No. *****
	
	US Patent Application No. *****
	
	US Patent Application No. *****
	
	US Provisional Patent Application No. *****
	
	US Provisional Patent Application No. *****

  



	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.